Cargando…
Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study
BACKGROUND: Mesenchymal stromal cells (MSC) may serve as an attractive therapy in renal transplantation due to their immunosuppressive and reparative properties. While most studies have used autologous MSCs, allogeneic MSCs offer the advantage of immediate availability for clinical use. This is of m...
Autores principales: | Reinders, Marlies E. J., Dreyer, Geertje J., Bank, Jonna R., Roelofs, Helene, Heidt, Sebastiaan, Roelen, Dave L., Zandvliet, Maarten L., Huurman, Volkert A. L., Fibbe, Wim E., van Kooten, Cees, Claas, Frans H. J., Rabelink, Ton J., de Fijter, Johan W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632480/ https://www.ncbi.nlm.nih.gov/pubmed/26537851 http://dx.doi.org/10.1186/s12967-015-0700-0 |
Ejemplares similares
-
Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single‐center study
por: Dreyer, Geertje J., et al.
Publicado: (2020) -
Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients
por: Reinders, Marlies EJ, et al.
Publicado: (2014) -
Autologous bone marrow‐derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single‐center, open‐label TRITON study
por: Reinders, Marlies E. J., et al.
Publicado: (2021) -
Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC
por: Dreyer, Geertje J., et al.
Publicado: (2023) -
Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients
por: Hendriks, Sanne H., et al.
Publicado: (2023)